De foreløbige resultater viste, at den generelle risiko for myopati var 0, 4%, og at indlæggelsesforekomsten for myopati i forbindelse med brug af cerivastatin i monoterapi ikke steg i forhold til de øvrige statiner.
The preliminary results suggested that the overall risk for myopathy was 0.4% and that the hospitalisation rate for myopathy associated with the use of cerivastatin monotherapy was not increased relative to the other statins.